- Home
- FURY vs ACOG Comparison
FURY vs ACOG Comparison
Compare FURY & ACOG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FURY
- ACOG
- Stock Information
- Founded
- FURY 2008
- ACOG 2000
- Country
- FURY Canada
- ACOG Canada
- Employees
- FURY N/A
- ACOG N/A
- Industry
- FURY Precious Metals
- ACOG
- Sector
- FURY Basic Materials
- ACOG
- Exchange
- FURY Nasdaq
- ACOG Nasdaq
- Market Cap
- FURY 84.1M
- ACOG 80.3M
- IPO Year
- FURY N/A
- ACOG N/A
- Fundamental
- Price
- FURY $0.71
- ACOG $9.55
- Analyst Decision
- FURY Strong Buy
- ACOG Strong Buy
- Analyst Count
- FURY 2
- ACOG 1
- Target Price
- FURY $1.40
- ACOG $20.00
- AVG Volume (30 Days)
- FURY 586.4K
- ACOG 71.3K
- Earning Date
- FURY 08-14-2025
- ACOG 08-14-2025
- Dividend Yield
- FURY N/A
- ACOG N/A
- EPS Growth
- FURY N/A
- ACOG N/A
- EPS
- FURY N/A
- ACOG N/A
- Revenue
- FURY N/A
- ACOG $4,586,341.00
- Revenue This Year
- FURY N/A
- ACOG N/A
- Revenue Next Year
- FURY N/A
- ACOG $149.89
- P/E Ratio
- FURY N/A
- ACOG N/A
- Revenue Growth
- FURY N/A
- ACOG N/A
- 52 Week Low
- FURY $0.35
- ACOG $3.75
- 52 Week High
- FURY $0.72
- ACOG $11.54
- Technical
- Relative Strength Index (RSI)
- FURY 78.57
- ACOG 60.24
- Support Level
- FURY $0.47
- ACOG $8.01
- Resistance Level
- FURY $0.72
- ACOG $8.34
- Average True Range (ATR)
- FURY 0.04
- ACOG 0.50
- MACD
- FURY 0.02
- ACOG 0.16
- Stochastic Oscillator
- FURY 96.08
- ACOG 94.39
About FURY Fury Gold Mines Limited
Fury Gold Mines Ltd is a Canadian-focused exploration and development company strategically positioned in three prolific mining regions: James Bay, Quebec; the Golden Triangle, British Columbia; and the Kitikmeot Region Nunavut. Its projects include Eau Claire, Homestake Ridge, Committee Bay, Eleonore South JV, and Gibson MacQuoid.
About ACOG Alpha Cognition Inc. Common Stock
Alpha Cognition Inc is a biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer's disease, for which there are limited or no treatment options. The Company's current focus is on the commercial manufacturing and sales of ZUNVEYL oral tablet formulation. The Company's commercial development program for ZUNVEYL is primarily focused on building a long-term care commercial team that can focus on providing key points of differentiation, exploiting key issues with existing Acetylcholinesterase inhibitors treatments, and seeking potential licensing partners for other additional indications and new formulations.